Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 1;8(8):1115-1126.
doi: 10.1001/jamaoncol.2022.1990.

Multilevel Factors Associated With Time to Biopsy After Abnormal Screening Mammography Results by Race and Ethnicity

Affiliations

Multilevel Factors Associated With Time to Biopsy After Abnormal Screening Mammography Results by Race and Ethnicity

Marissa B Lawson et al. JAMA Oncol. .

Abstract

Importance: Diagnostic delays in breast cancer detection may be associated with later-stage disease and higher anxiety, but data on multilevel factors associated with diagnostic delay are limited.

Objective: To evaluate individual-, neighborhood-, and health care-level factors associated with differences in time from abnormal screening to biopsy among racial and ethnic groups.

Design, setting, and participants: This prospective cohort study used data from women aged 40 to 79 years who had abnormal results in screening mammograms conducted in 109 imaging facilities across 6 US states between 2009 and 2019. Data were analyzed from February 21 to November 4, 2021.

Exposures: Individual-level factors included self-reported race and ethnicity, age, family history of breast cancer, breast density, previous breast biopsy, and time since last mammogram; neighborhood-level factors included geocoded education and income based on residential zip codes and rurality; and health care-level factors included mammogram modality, screening facility academic affiliation, and facility onsite biopsy service availability. Data were also assessed by examination year.

Main outcome and measures: The main outcome was unadjusted and adjusted relative risk (RR) of no biopsy within 30, 60, and 90 days using sequential log-binomial regression models. A secondary outcome was unadjusted and adjusted median time to biopsy using accelerated failure time models.

Results: A total of 45 186 women (median [IQR] age at screening, 56 [48-65] years) with 46 185 screening mammograms with abnormal results were included. Of screening mammograms with abnormal results recommended for biopsy, 15 969 (34.6%) were not resolved within 30 days, 7493 (16.2%) were not resolved within 60 days, and 5634 (12.2%) were not resolved within 90 days. Compared with White women, there was increased risk of no biopsy within 30 and 60 days for Asian (30 days: RR, 1.66; 95% CI, 1.31-2.10; 60 days: RR, 1.58; 95% CI, 1.15-2.18), Black (30 days: RR, 1.52; 95% CI, 1.30-1.78; 60 days: 1.39; 95% CI, 1.22-1.60), and Hispanic (30 days: RR, 1.50; 95% CI, 1.24-1.81; 60 days: 1.38; 95% CI, 1.11-1.71) women; however, the unadjusted risk of no biopsy within 90 days only persisted significantly for Black women (RR, 1.28; 95% CI, 1.11-1.47). Sequential adjustment for selected individual-, neighborhood-, and health care-level factors, exclusive of screening facility, did not substantially change the risk of no biopsy within 90 days for Black women (RR, 1.27; 95% CI, 1.12-1.44). After additionally adjusting for screening facility, the increased risk for Black women persisted but showed a modest decrease (RR, 1.20; 95% CI, 1.08-1.34).

Conclusions and relevance: In this cohort study involving a diverse cohort of US women recommended for biopsy after abnormal results on screening mammography, Black women were the most likely to experience delays to diagnostic resolution after adjusting for multilevel factors. These results suggest that adjustment for multilevel factors did not entirely account for differences in time to breast biopsy, but unmeasured factors, such as systemic racism and other health care system factors, may impact timely diagnosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Miglioretti reported receiving personal fees from Elsevier. Dr Chapman reported receiving personal fees from the American Society of Clinical Oncology and National Comprehensive Cancer Network Elevating Cancer Equity Workgroup and grants from the National Cancer Institute (NCI) Cancer Intervention and Surveillance Modeling Network (CISNET) outside the submitted work. Dr Kerlikowske reported serving as an unpaid consultant for GRAIL. Dr Gard reported receiving personal fees from Kaiser Permanente Washington Health Research Institute outside the submitted work. Dr Lee reported receiving personal fees from GE Healthcare, GRAIL, American College of Radiology, McGraw Hill, UpToDate, Wolters Kluwer, and Oxford University Press all outside submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Flowchart of Study Cohort Selection
aScreening mammograms were excluded if the woman was symptomatic at the time of the examination or had a personal history of breast cancer.
Figure 2.
Figure 2.. Time to Biopsy Curves Following Abnormal Screening Mammogram Results by Race and Ethnicity

Comment in

Similar articles

Cited by

References

    1. Kaplan HG, Malmgren JA, Atwood MK, Calip GS. Effect of treatment and mammography detection on breast cancer survival over time: 1990-2007. Cancer. 2015;121(15):2553-2561. doi:10.1002/cncr.29371 - DOI - PMC - PubMed
    1. Berry DA, Cronin KA, Plevritis SK, et al. ; Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators . Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784-1792. doi:10.1056/NEJMoa050518 - DOI - PubMed
    1. Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L. Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med. 2016;164(4):244-255. doi:10.7326/M15-0969 - DOI - PubMed
    1. Rutter CM, Kim JJ, Meester RGS, et al. . Effect of time to diagnostic testing for breast, cervical, and colorectal cancer screening abnormalities on screening efficacy: a modeling study. Cancer Epidemiol Biomarkers Prev. 2018;27(2):158-164. doi:10.1158/1055-9965.EPI-17-0378 - DOI - PMC - PubMed
    1. Ganry O, Peng J, Dubreuil A. Influence of abnormal screens on delays and prognostic indicators of screen-detected breast carcinoma. J Med Screen. 2004;11(1):28-31. doi:10.1177/096914130301100107 - DOI - PubMed

Publication types